
==== Front
BMJ Open
BMJ Open
bmjopen
bmjopen
BMJ Open
2044-6055
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

10.1136/bmjopen-2022-070823.corr1
bmjopen-2022-070823.corr1
Correction
Correction: ‘Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOPCABG trial study’
2024
10 7 2024
10 7 2024
14 7 e070823.corr1Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
==== Body
pmc Yuan X, Chu Q, Chen K, et al. Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOPCABG trial study. BMJ Open 2023;13:e070823. doi:10.1136/bmjopen-2022-070823

This article has been corrected since it was published online. The Sample size has been updated from “Primary efficacy endpoint: patency in De-DAPT group is non-inferior to DAPT group. We assumed that the 1-year SVG occlusion rate would be 10% with De-DAPT and DAPT and non-inferiority margin would be 3.0%.” to “Primary efficacy endpoint: patency in De-DAPT group is non-inferior to DAPT group. We assumed that the 1-year SVG occlusion rate would be 10% with DAPT and non-inferiority margin would be 3.5%.”
